Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.

The firm in question, TRC Capital Investment Corp., has a history of making below-market offers to shareholders of large corporations. These offers are typically unsolicited. 

Researchers examined data from nearly 2 million patients, sharing their full findings in JACC: Cardiovascular Imaging.

Northwestern's Clyde Yancy, MD, discusses how his health system is addressing health access equity issues with plans to open a new outpatient clinic on the historically Black Chicago South Side.

The partnership is with ScImage, a California-based healthcare technology company known for its extensive EI background.

AVS, a Michigan-based medical device company, has said the funding will help accelerate research on its new Pulse P-IVL system. One clinical trial is already underway.